27 Aug
2021

First FDA interchangeable approval is a potential gamechanger for biosimilar patent strategy

The US FDA has approved the country’s first interchangeable biosimilar. The launch of more such drugs in the coming years could alter the biosimilar IP playbook

Adam Houldsworth

Author | Life sciences reporter

[email protected]

Adam Houldsworth